B. Riley raised the firm’s price target on Perspective Therapeutics (CATX) to $12 from $9 and keeps a Buy rating on the shares. The firm says sequential positive updates from Perspective drive the higher price target It now sees an increased probabiliry of success for VMT-alpha-NET to deliver best-in-class efficacy and safety profile.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CATX:
- Optimistic Buy Rating for Perspective Therapeutics Driven by Strategic Developments and Promising Clinical Data
- Perspective Therapeutics commences recruitment for 212PbVMT-alpha-NET
- Perspective Therapeutics Updates on Radiopharmaceutical Advancements
- Perspective Therapeutics price target raised to $16 from $15 at RBC Capital
- Promising Clinical Trial Results and Safety Profile Drive Buy Rating for Perspective Therapeutics